Treatment with Anti-Tumor Necrosis Factor (anti-TNF) therapy has become a mainstay of therapy for patients with CD who are unresponsive to conventional medical management. Currently there are three anti-TNF antibodies that have been approved by the US Food and Drug Administration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP). Several double blind placebo controlled trials determined that CZP is effective as induction and maintenance treatment in adult patients with CD regardless of their prior exposure to other anti-TNF antibodies. This review discusses the efficacy of CZP and adherence to therapy with anti-TNF antibodies in patients with CD.
PDF (563.81 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
Supplementary Files 1 (8.79 MB WMV FORMAT)
BibTex citation (BIBDESK, LATEX)
I have had a great experience with submitting my cancer prognosis study to Biomarker Insights. The comments from reviewers and associate editor are high quality and insightful. Congratulations and keep up the good work.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)